The findings highlight the critical role of Kir4.1 channels in MS pathogenesis and suggest that pharmacological activation of these channels by 2‐D08 can be a promising therapeutic strategy for enhancing brain recovery in demyelinating diseases. This evidence concerns the gene KCNJ10 and demyelinating disease.